Copyright
©The Author(s) 2022.
World J Clin Cases. Feb 16, 2022; 10(5): 1580-1585
Published online Feb 16, 2022. doi: 10.12998/wjcc.v10.i5.1580
Published online Feb 16, 2022. doi: 10.12998/wjcc.v10.i5.1580
Figure 2 Computed tomography of the lung.
A: First computed tomography (CT) scan showing thickening of the upper right lobe cavity (October 9, 2017); B: Figure showing reduction of the tumor and enlarged cavity after 4 cycles of chemotherapy (pemetrexed + cisplatin); C: Increase in tumor size 4 mo after the last chemotherapy session (June 11, 2018); D: After the patient had received radiotherapy, CT showed that the tumor began to shrink, (August 2, 2018) the tumor had reduced in size, and anlotinib was initiated (orally, 12 mg once daily from days 1 to 14 of a 21-d cycle); E: On May 1, 2019, the tumor started to enlarge but cavity enlargement was resolved; hence, nivolumab treatment was started (5 times, from May 6, 2019 to August 19, 2019); F: In August 12, 2019, the upper right lung mass was significantly smaller than that observed before the cavity enlarged.
- Citation: Deng PB, Jiang J, Hu CP, Cao LM, Li M. Tumor-related cytokine release syndrome in a treatment-naïve patient with lung adenocarcinoma: A case report . World J Clin Cases 2022; 10(5): 1580-1585
- URL: https://www.wjgnet.com/2307-8960/full/v10/i5/1580.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i5.1580